Navigation Links
Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
Date:1/31/2012

DURHAM, N.C., Jan. 31, 2012 /PRNewswire/ -- Argos Therapeutics Inc., today announced that it presented a high resolution immune monitoring analysis of AGS-003-006, a Phase 2 study of its Arcelis™ immunotherapy, AGS-003, in combination with sunitinib in patients with advanced renal cell carcinoma (RCC). The results showed a statistically significant correlation between anti-tumor memory T cell responses and overall survival. AGS-003 in combination with sunitinib overcame the immuno-suppressive environment of RCC and induced a tumor-specific multi-functional memory CTL response. The results were presented orally at the Global Technology Community's (GTC) 4th Immunotherapeutics and Immunomonitoring Conference in San Diego.

"We believe that the high resolution immune monitoring analysis of the Phase 2 study of AGS-003 and sunitinib represents the first time that pattern recognition algorithms originally developed for gene microarray datasets have been applied to an immunologic dataset to identify immune correlates to clinical outcome," said Charles Nicolette, Ph.D., Argos' chief scientific officer and vice president of research and development. "The multiparametric flow cytometry data from the study that we analyzed demonstrated that the combination of AGS-003 and sunitinib induced tumor-specific multi-functional memory CTL that were statistically significant correlates to overall survival in the study, thereby supporting the intended mechanism of action of AGS-003."

AGS-003-006 was an open label Phase 2 trial of AGS-003 in combination with sunitinib in patients with newly diagnosed, unfavorable-risk, metastatic clear cell RCC. AGS-003 was designed to stimulate the proliferation and multi-functionality of CTLs targeted directly to the autologous RCC tumor antigens.  In analyzing the data from the trial we sought to detect immune correlates by using multi-parametric flow cytometry to identify 16 unique RCC antigen reactive CTL subsets ba
'/>"/>

SOURCE Argos Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Argos Therapeutics to Present Corporate Overview and Next Steps in Clinical Development of Arcelis™ Immunotherapy at Lazard Capital Markets 7th Annual Healthcare Conference
2. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
3. Healthpoint Biotherapeutics to Present at 30th Annual J.P. Morgan Healthcare Conference
4. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
5. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
6. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
7. Amsterdam Molecular Therapeutics Announces € 2.5 Million Equity Raise
8. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
9. Silence Therapeutics Additional Listing
10. Access BridgeGap Ventures to Focus on Early-Stage Therapeutic Opportunities
11. MarketsandMarkets: Acute Myeloid Leukemia Therapeutics Market in G8 Countries Worth $1.67 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... ... 26, 2015 , ... Lee Biosolutions, a global biotech healthcare ... of highly valued cardiac markers used in early detection of heart disease due ... has led to the development and commercialization of important cardiac biomarkers used in ...
(Date:8/26/2015)... JERUSALEM and BEIJING , August 26, ... Startup Scene with Impressive Acheivements  DiaCardio wins 1 st ...   The competition, led in Israel ... ‎, featured 21 startups from countries including the US, ... and Latin America .  ...
(Date:8/26/2015)... ... August 26, 2015 , ... PRC Clinical, a Clinical Trial Management ... local sponsors in southern California. The Clinical Trial Management Expert CRO seeks to introduce ... pathways., , Stem Cell Meeting on the Mesa ...
(Date:8/25/2015)... ... August 25, 2015 , ... Vets Plus, Inc. recently installed ... company has added a AS16 Sharples centrifuge to harvest products after fermentation. The ... fungal fermentation process development. , The new centrifuge greatly expands production capabilities ...
Breaking Biology Technology:Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3New centrifuge and fermentor expand product development capacity at Vets Plus 2
... Host Update Conference Call Today at 8:30 a.m. EST, ... RIGL ) today reported financial results for,the three and ... quarter of 2008, Rigel reported a net loss of $37.7,million, ... $18.9 million, or,$0.61 per share, in the third quarter of ...
... Inc. (Nasdaq: VNUS ), a leading provider of ... disease, today,announced the hiring of Guido Smeets, MD, as ... Dr. Smeets joins VNUS with over 17 years of ... the Head of Clinical Affairs for,Pelikan Technologies, Inc., a ...
... Calif., Oct. 31 SleepQuest has always,followed the essence ... suffer from,undiagnosed and unexplained health problems related to lack ... discuss the,importance of identifying and treating sleep disorders. Sleep ... as a wellness factor.,Studies done by the National Commission ...
Cached Biology Technology:Rigel Announces Third Quarter 2008 Financial Results and Clinical Update 2Rigel Announces Third Quarter 2008 Financial Results and Clinical Update 3Rigel Announces Third Quarter 2008 Financial Results and Clinical Update 4Rigel Announces Third Quarter 2008 Financial Results and Clinical Update 5Rigel Announces Third Quarter 2008 Financial Results and Clinical Update 6VNUS Medical Technologies, Inc. Announces the Hiring of Guido Smeets, MD, as Vice President of Clinical Research and Chief Medical Officer 2SleepQuest Tireless in Pursuit of Good Sleep 2
(Date:8/12/2015)... 12, 2015  New research unveiled at Black ... phones to steal users, fingerprints. Information released today ... fingerprint scanners on mobile devices, making the security ... biometrics on mobile devices, HYPR Corp. recently released ... authentication systems with strong cryptographic security. More information ...
(Date:8/6/2015)... REDWOOD CITY, Calif. , Aug. 6, 2015 ... (D-Silicon Valley) will visit Crossmatch ™ to ... secure networks and protect data. Crossmatch is a ... solutions whose technologies and expertise are helping federal ... operational efficiency and security.   "The ...
(Date:8/5/2015)... Aug. 5, 2015 The biosensors market is ... applications, penetration into newer sectors, and development of devices ... biosensors space has seen the entry of multiple participants ... far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... Analysis of the Global Biosensors Market ( http://www.frost.com/nee9 ...
Breaking Biology News(10 mins):HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3Rep. Honda to Visit Crossmatch in Redwood City 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4
... Researchers at Wayne State University have discovered a ... undergoing hemodialysis that may prevent cardiovascular disease common in ... at a greater risk for atherosclerosis, a common disease ... can lead to serious problems including heart attack, stroke ...
... KAN. -- People who decrease sitting time and increase ... according to Kansas State University research. Even standing ... at a time -- can improve health and quality ... such as cardiovascular disease, diabetes, heart disease, stroke, breast ...
... initiative bridges the gap between research and the market. ... processes that protect the environment become fully-fledged commercial prospects, ... new product is intended for the aeronautic market, where ... to conventional Cr-based coatings, which provide optimum corrosion protection, ...
Cached Biology News:Wayne State discovers potential treatment for better heart health in hemodialysis patients 2Take a stand and be active to reduce chronic disease, make aging easier, research finds 2The Eco-Innovation initiative rewards ideas for innovative products that protect the environment 2
... Immunogen: Synthetic peptide derived from the ... Specificity: Specific for the junctophilin-1 ... mouse brain and skeletal muscle homogenates ... tissues). Applications: Western blotting Immunohistochemistry(froz) ...
Request Info...
Laminin beta-1/gamma-1 (612C10)...
HSV 1 IgM...
Biology Products: